Aclarion, INC 8-K filings

Aclarion Inc. has entered into a subscription agreement to sell 400,000 shares of common stock at $0.29 per share, raising $116,000.

Aclarion, Inc. has announced its first payer coverage for its Nociscan product by AXA, a major private medical insurer in the UK, marking a significant step towards commercialization.

Aclarion Inc. has amended its bylaws to lower the quorum requirement for stockholder meetings from a majority to one-third of voting power.

Aclarion, Inc. has raised $304,500 by selling 1.05 million shares of common stock through its existing equity line facility.

Aclarion, Inc. has received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share, giving them 180 days to regain compliance.

Aclarion, Inc. successfully closed a $3 million public offering to address Nasdaq listing requirements and fund operations.

Aclarion Inc. has released its audited financial statements for 2023 and 2022, highlighting recurring losses and substantial doubt about the company's ability to continue as a going concern.

Aclarion Inc. has issued 500,000 shares of common stock to exchange approximately $1.185 million of debt and accrued interest, increasing its total outstanding shares to 1,791,375.

Aclarion Inc. has entered into an exchange agreement with accredited investors to convert a portion of its outstanding debt into common stock.